LA
JSPR icon

Linden Advisors’s Jasper Therapeutics JSPR Stock Holding History

Linden Advisors’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,769
Closed -$1.27M – 832
2021
Q1 		$1.27M Sell
12,769
-369
-3% -$37.5K 0.01% 485
2020
Q4 		$1.32M Hold
13,138
– – 0.01% 359
2020
Q3 		$1.3M Hold
13,138
– – 0.02% 235
2020
Q2 		$1.33M Hold
13,138
– – 0.02% 176
2020
Q1 		$1.26M Buy
+13,138
New +$1.29M 0.02% 153

Other funds holding JSPR

MSU
Mizuho Securities USA New York $4.24B AUM 22.54% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return
KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $879M AUM 29.99% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return

Linden Advisors's JSPR Position: Q2 2021 in Review

Linden Advisors sold out of Jasper Therapeutics (JSPR) in Q2 2021, closing a stake of 12,769 shares — an estimated $1.27M sold.

Linden Advisors first reported a position in JSPR in Q1 2020 and held it in 5 quarters. The position peaked at $1.33M in Q2 2020. 57 funds tracked by Wall St. Rank hold JSPR as of Q2 2021.

  • Linden Advisors reported no remaining Jasper Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Linden Advisors sold 12,769 Jasper Therapeutics shares in Q2 2021, an estimated $1.27M.
  • Linden Advisors first reported a position in Jasper Therapeutics in Q1 2020 and held it in 5 quarters.
  • Linden Advisors's Jasper Therapeutics position peaked at $1.33M in Q2 2020.
  • 57 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2021.

Based on Linden Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.